← Back to Search

Placental Function Assessment for High-Risk Pregnancies

Phase 1
Waitlist Available
Led By Eileen P. Sloan, MD
Research Sponsored by Mount Sinai Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Over 18 years of age
Normal karyotype
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cross-sectional
Awards & highlights

Study Summary

This trial will test whether or not reducing anxiety in high-risk pregnant women through blood tests and ultrasounds improves outcomes for mother and child.

Who is the study for?
This trial is for pregnant women over 18, fluent in English, with high-risk pregnancies due to conditions like diabetes or high blood pressure. They must be patients at Mount Sinai Hospital's maternal/fetal unit without major fetal abnormalities or genetic issues and able to consent.Check my eligibility
What is being tested?
The study tests if assessing placental function through blood tests and ultrasound can reduce anxiety in these women by reassuring them about their baby's health. Half the participants will receive this assessment randomly while the other half won't, to measure any differences accurately.See study design
What are the potential side effects?
There are no direct side effects from the placental function assessment itself as it involves standard pregnancy blood tests and an ultrasound which are routine procedures during prenatal care.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 years old.
Select...
My chromosomes are normal.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cross-sectional
This trial's timeline: 3 weeks for screening, Varies for treatment, and cross-sectional for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
measure is STAI - The State Trait Anxiety Inventory
Secondary outcome measures
Women who undergo the placental function assessment will deliver at a later gestation age, have less complications and stillbirths than untested women. Neonates will have higher APGAR scores at 1 and 5 minutes and less likely to be admitted to the NICU.

Trial Design

1Treatment groups
Active Control
Group I: Active groupActive Control1 Intervention
Receive assessment of placental function

Find a Location

Who is running the clinical trial?

Mount Sinai Hospital, CanadaLead Sponsor
196 Previous Clinical Trials
67,448 Total Patients Enrolled
Ontario Mental Health FoundationOTHER_GOV
23 Previous Clinical Trials
3,214 Total Patients Enrolled
Eileen P. Sloan, MDPrincipal InvestigatorMount Sinai Hospital, Canada

Media Library

Placental Function Assessment Clinical Trial Eligibility Overview. Trial Name: NCT00546026 — Phase 1
Pregnancies Research Study Groups: Active group
Pregnancies Clinical Trial 2023: Placental Function Assessment Highlights & Side Effects. Trial Name: NCT00546026 — Phase 1
Placental Function Assessment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00546026 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent might Active group present a hazard to those under its care?

"Our team at Power has assigned Active group a score of 1, as it is currently in Phase 1 and there is minimal evidence to support its safety or efficacy."

Answered by AI
~107 spots leftby Apr 2025